# Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

> **NCT05284799** · PHASE2 · COMPLETED · sponsor: **Osivax** · enrollment: 180 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** OVX836 480µg
- **BIOLOGICAL:** Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05284799
- **Lead sponsor:** Osivax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-12-09
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284799, "Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05284799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*